Raphael Pharmaceutical Inc. (RAPH)
| Market Cap | 28.25M |
| Revenue (ttm) | n/a |
| Net Income | -1.28M |
| EPS | -0.07 |
| Shares Out | 20.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 278 |
| Open | 1.400 |
| Previous Close | 0.052 |
| Day's Range | 1.400 - 1.400 |
| 52-Week Range | 0.040 - 1.400 |
| Beta | 2.00 |
| RSI | 52.91 |
| Earnings Date | Apr 13, 2026 |
About Raphael Pharmaceutical
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative resea...
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing * Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate ...
Raphael Pharmaceutical Issues Letter to Shareholders
Highlights Company's exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently co...